Even with a relatively common mutation (e.g. KRAS mutation in non-small cell lung cancer) it is challenging to partition the available cell lines into distinct discovery and validation sets while maintaining statistical power to identify potential dependencies. Here, KRAS is linked to non-small cell lung carcinoma.